Fiasp PumpCart (insulin aspart)
- Former
- Injektionsvæske i patron
- Styrke
- 100 enheder/mL
- Alternativer
- Ja
Fiasp PumpCart (insulin aspart) INN: insulin aspart
What is this? Fiasp PumpCart is a cartridge filled with insulin aspart. It is used in insulin pumps to help control blood sugar.
What's happening? There is a shortage of Fiasp PumpCart cartridges in the EU. Supplies are running low.
Does this affect me? If you use Fiasp PumpCart in an insulin pump, you may be affected by this shortage.
What should I do? Talk to your pharmacist or doctor about other insulin options that are available.
🤖 Denne letforståelige oversigt er automatisk genereret ud fra den officielle meddelelse fra myndigheden ved hjælp af AI. Den er udelukkende til generel information — ikke medicinsk rådgivning. Vedrørende beslutninger om din sundhed, skal du altid konsultere en farmaceut eller læge og læse den officielle kilde, der er linket nedenfor.
📋 Fra den officielle meddelelse fra myndigheden
Opdateret for 1 uge siden- Senest opdateret
- 18/12/2025
- Først udgivet
- 12/05/2025
- Berørte lægemidler
- Fiasp PumpCart (insulin aspart)
- Berørte styrker
- 100 units/mL
- Lagerstatus
- Ongoing
- Start på forsyningsmangel
- 08/05/2025
- Tilgængelighed af alternativer
- Yes
- Berørte lægemiddelformer
- Solution for injection in a cartridge
- Internationalt ikke-ejendomsretligt navn (INN) eller fællesnavn
- insulin aspart
Sideindhold
Mangel på lager
There is a shortage of Fiasp PumpCart in the EU (European Union) / EEA (European Economic Area).
Fiasp is a medicine that is used to treat children from one year of age and adults with diabetes. It contains the active substance insulin aspart, a fast-acting insulin. The Fiasp PumpCart is one of presentations of this medicine.
For further information on the use of the medicine please refer to the medicine’s overview page.
The current manufacturing capacity for Fiasp PumpCart cannot meet demand. This has led or may lead to intermittent shortages of Fiasp PumpCart. The shortages are not related to a quality defect of the product or a safety issue.
In addition, the company marketing Fiasp will discontinue Fiasp PumpCart for commercial reasons by the end of 2026 at the latest in all EU/EEA countries where the product is currently marketed.
All Member States where the product is marketed are currently affected or are at risk of being affected by the intermittent shortages: Belgium, Denmark, Finland, France, Germany, Ireland, Luxembourg, Netherlands, Norway, Spain and Sweden.
For up-to-date information about the status of a medicine shortage in a particular Member State, consult the national shortage register or contact the national competent authority.
EMA’s Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) and EMA’s shortages working party (Medicines Shortages Single Point of Contact – SPOC - working party) are closely monitoring the supply situation and engaging with the marketing authorisation holder and other stakeholders to mitigate the impact of the supply shortage and prepare for the discontinuation in 2026.
- No new patients should be started on Fiasp PumpCart.
- In case Fiasp PumpCart is unavailable, healthcare professionals should switch existing patients to alternative fast-acting insulin treatment based on existing guidance and clinical judgment. Other fast-acting insulins include:
- Fiasp, NovoRapid or insulin aspart biosimilars;
- insulin lispro or its biosimilars;
- Insulin glulisine or its biosimilars;
- A medicine shortage communication (MSC) has been sent to healthcare professionals in affected Member States and is also available on the EMA website.
- For additional information, consult your country’s shortage register or contact your national competent authority.
- Contact your healthcare professional well before your current supply runs out.
- If you use Fiasp PumpCart regularly, your healthcare professional will discuss an alternative insulin medicine with you.
- Your healthcare professional will ensure that you receive guidance on any changes and provided with adequate training.
- If you have any questions, speak to your doctor or pharmacist.
- For additional information, consult your country’s shortage register or contact your national competent authority.
Årsag til mangel
The current manufacturing capacity for Fiasp PumpCart cannot meet demand. This has led or may lead to intermittent shortages of Fiasp PumpCart. The shortages are not related to a quality defect of the product or a safety issue.
In addition, the company marketing Fiasp will discontinue Fiasp PumpCart for commercial reasons by the end of 2026 at the latest in all EU/EEA countries where the product is currently marketed.
Berørte medlemsstater
All Member States where the product is marketed are currently affected or are at risk of being affected by the intermittent shortages: Belgium, Denmark, Finland, France, Germany, Ireland, Luxembourg, Netherlands, Norway, Spain and Sweden.
For up-to-date information about the status of a medicine shortage in a particular Member State, consult the national shortage register or contact the national competent authority.
Overvågning af mangel
EMA’s Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) and EMA’s shortages working party (Medicines Shortages Single Point of Contact – SPOC - working party) are closely monitoring the supply situation and engaging with the marketing authorisation holder and other stakeholders to mitigate the impact of the supply shortage and prepare for the discontinuation in 2026.
Anbefalinger til sundhedspersonale
- No new patients should be started on Fiasp PumpCart.
- In case Fiasp PumpCart is unavailable, healthcare professionals should switch existing patients to alternative fast-acting insulin treatment based on existing guidance and clinical judgment. Other fast-acting insulins include:
- Fiasp, NovoRapid or insulin aspart biosimilars;
- insulin lispro or its biosimilars;
- Insulin glulisine or its biosimilars;
- A medicine shortage communication (MSC) has been sent to healthcare professionals in affected Member States and is also available on the EMA website.
- For additional information, consult your country’s shortage register or contact your national competent authority.
Anbefalinger til patienter og pårørende
- Contact your healthcare professional well before your current supply runs out.
- If you use Fiasp PumpCart regularly, your healthcare professional will discuss an alternative insulin medicine with you.
- Your healthcare professional will ensure that you receive guidance on any changes and provided with adequate training.
- If you have any questions, speak to your doctor or pharmacist.
- For additional information, consult your country’s shortage register or contact your national competent authority.
Nøgleoplysninger
- Medicines affected
- Fiasp PumpCart (insulin aspart)
- Supply shortage status
- Ongoing
- International non-proprietary name (INN) or common name
- insulin aspart
- Pharmaceutical forms affected
- Solution for injection in a cartridge
- Strengths affected
- 100 units/mL
- Availability of alternatives
- Yes
Nøgledatoer
- Start of supply shortage
- First published
- Last updated
Relateret medicinsk information
🔬 Medicinske/tekniske detaljer Til fagfolk
INN: insulin aspart · Forms: Solution for injection in a cartridge · Strengths: 100 units/mL · Alternatives: Yes
Alle oplysninger på denne side stammer fra den officielle meddelelse fra myndighederne. Vi oversætter og opsummerer den; vi tilføjer eller redigerer ikke fakta.